Iran’s attacks stoke worries on Wall Street

Join TradeAlgo's Free Live Trading Session ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ [EARN WHILE YOU LEARN! JOIN OUR FREE LIVE TRADING SESSION!]( Hello investor, Iran’s attacks stoke worries on Wall Street Iran’s attack over the weekend sparked a new level of anxiety on Wall Street, as investors were already worried about sticky inflation that will keep interest rates higher for longer. The attack raises the odds that Iran could get involved in the Israel-Hamas conflict. Some analysts believe oil prices can soar above $100 a barrel. As a result, investors could flock to Treasuries, gold and the dollar. If they do, that would mean less cash in the stock market. However, Iran said “the matter can be deemed concluded.” It hints that Iran is not interested in getting involved with the conflict any further. What’s more, President Biden reportedly told Israeli Prime Minister Benjamin Netanyahu that the US will not support any counterattack against Iran, so an escalation isn’t guaranteed. - “Investors’ natural reaction is to look for safe-haven assets in moments like this,” said Patrick Armstrong, chief investment officer at Plurimi Wealth LLP. “Reactions will be somewhat dependent on Israel’s response. If Israel does not escalate from here, it may provide an opportunity to buy risk assets at lower prices.” Patrick Armstrong, chief investment officer at Plurimi Wealth LLP (Photo: CNBC) Bitcoin originally nosedived by almost 9% after the report of attacks hit the press, but it rebounded to reach around $64,000 yesterday. If it is any indicator, the reaction may not be too violent today. (At least for now.) Oil prices, however, may still rise. It could affect the central bank’s fight against inflation if prices continue to gain. Brent crude jumped about 20% this year and is now trading at around $90 a barrel. - “Middle Eastern markets opened with relative calm following Iran’s attack, which was perceived as a measured retaliation, rather than an attempt at escalation,” said Emre Akcakmak, a senior consultant at East Capital in Dubai. - “However, the market impact might extend beyond the Middle East due to secondary effects on oil and energy prices, potentially influencing the global inflation outlook.” As for this week’s earnings, we will get more earnings reports from big banks — including Charles Schwab, Goldman Sachs, and Bank of America. Regional banks (such as M&T Bank) will be in the spotlight to see how higher-for-longer rates will affect their businesses. Here are the list of notable companies reporting results this week: - Monday: Charles Schwab, Goldman Sachs, M&T Bank - Tuesday: UnitedHealth Group, Bank of America, BNY Mellon, Commerce Bancshares, Johnson & Johnson, Morgan Stanley, Northern Trust, PNC, Interactive Brokers, J.B. Hunt Transport, United Airlines - Wednesday: Abbott Laboratories, ASML, Citizens Financial Group, First Horizon, Prologis, Travelers Companies, U.S. Bancorp, Alcoa, Bank of OZK, CSX, Discover Financial Services, Equifax, Las Vegas Sands, Wintrust Financial - Thursday: Netflix, Alaska Air, Ally Financial, Blackstone, Comerica, D.R. Horton, KeyCorp, Manpower, Marsh & McLennan, Snap-On - Friday: Procter & Gamble, American Express, Fifth Third Bancorp, Huntington Bancshares, Regions Financial, SLB (Photo: Aaronp / Getty Images) Top Growth Stock With Massive Profit Margins Today’s Stock Pick: Inspire Medical Systems (INSP) You know that the only thing we love more than compound annual growth is compound quarterly growth. Well, today’s company has grown nearly all y-o-y quarters except for one over the past 20 quarters. (Source: MacroTrends) So how exactly are they doing it? Inspire Medical offers a minimally invasive procedure that treats obstructive sleep apnea. - Obstructive sleep apnea blocks patients’ airways while they’re sleeping. The frequency of airway blockage ranges from hourly to more than a hundred times a night. - This means that people can go through long stretches without any oxygen, increasing chances of strokes or cardiac death. At best, those suffering from sleep apnea report insomnia-like sleep quality. (Source: Inspire Medical Systems) Why does Inspire’s new sleep apnea treatment matter? Let’s say you had sleep apnea. Before Inspire, there were two ways to treat it. - You can have the back of your mouth and top of your throat cut up in a surgery that permanently alters your anatomy. The procedure also takes weeks to recover from. (Source: Inspire Medical Systems) - You can wear one of these masks for 6-8+ hours every night. The masks have to be strapped onto your head so they don’t move. There’s nose-only options if you’re willing to tape or strap your mouth shut. (Source: ResMed) Inspire’s implant takes just two hours to put in place. Patients can return to everyday life mere days later. - The device stimulates the nervous system when airways are obstructed. The device is built on a closed-loop system and has 11-year battery life. (Source: Inspire Medical Systems, Inc. Q2 2021 Investor Presentation) Clinical trials show that the treatment works, with the apnea hypopnea index for the frequency of events dropping by a factor of 3.25-4.72 in the 1-5 years post-treatment. Oxygen desaturation (lack of oxygen) during sleep also goes down by a factor of 3.43-5.52 in the same time period. - Just as importantly, patients who withdrew from the treatment saw more than 80% of the symptoms return. (Source: Inspire Medical Systems) Inspire’s patients report 45% less daytime sleepiness. As an added bonus, 81-90% of patients or their partners report a significant improvement in snoring volume. (Source: Inspire Medical Systems) That’s great, what about going forward? Management expects ~25% revenue growth this year. CEO Tim Herbert says that physicians and patients are practically breaking down the doors to get this new sleep apnea treatment. - “We have a significant demand from physicians and centers to open new centers,” Mr. Herbert told analysts. And when customers demand your product, the margins are fantastic. While Inspire is currently not showing profits, its 84% gross margins point to serious pricing power. (Source: Inspire Medical Systems) Bottom Line: Inspire Medical Systems might have one of the most blatantly obvious moats we’ve seen. When the alternative looks like this: (Source: New York Advanced Center For Specialty Care) But feels like this: (Source: Jared Gray | Facebook) This is simply a must-own stock for your portfolio to own a piece of the breakthrough in sleep apnea that will improve tens of thousands of people’s lives instantly. [EARN WHILE YOU LEARN! JOIN OUR FREE LIVE TRADING SESSION!](       © All Rights Reserved, Trade Alliance [Unsubscribe]( | [Manage Preferences](